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The creation of new technologies and their application to forensic science is key to the field's 
development. Rapid DNA profiling is one such area of research which has grown in response to a 
desire from enforcement authorities for in-house forensic DNA processing and rapid access to 
forensic genetic intelligence. However, introducing novel technologies into the forensics market 
must be carefully monitored and controlled as the success or failure of any technology ultimately 
has long standing implications for victims, suspects, and also to Police and forensic practitioners. 
This article outlines the research, development, validation and implementation of the ParaDNA® 
Screening System as a case study in taking forensic research and development to market. 
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1. Introduction 
A key topic of discussion at Forensic Horizons 2013 was taking research and development (R&D) to 
market with many different stakeholders identifying the need to make this process easier. Launching 
new DNA based products and platforms into the forensics market place can be complicated and can 
take an extended period of time. A large amount of time is inevitably spent in development but 
there is also a large amount of time spent generating data to support the technology and its 
proposed application. Such data may be generated to test the scientific underpinning of the 
technology in question whilst additional data may be generated to address the requirements of 
stakeholders. The large number of stakeholders that exist in the forensic community includes 
government and non-government parties, private industry, academia, the Criminal Justice System 
and ultimately the general public. Given the diversity of the interested parties involved there are 
inevitably a number of equally valid, but not always similarly prioritised requirements and concerns 
that need addressing which takes time. Having some awareness of the stakeholder groups and their 
requirements will facilitate the movement of technology from research through development and 
ultimately into operational deployment in the Criminal Justice System, intelligence gathering, and 
defence and security applications [1]. 
The ParaDNA Screening System has recently undergone such a transition from proof of concept to 
operationally deployed product. The ParaDNA Screening System consists of a sampling device, pre-
loaded reaction plates and detection instrument. The test uses direct PCR with fluorescent 
HyBeacon™ probe detection [2] of PCR amplicons to identify the presence of human DNA on an 
evidence item and gender identification in approximately 75min. This simple-to-use design allows 
objective data to be acquired by both trained DNA analysts and non-specialist personnel, to enable 
more informed submission decisions to be made.  
For any product to be deemed a success it has to fulfil a basic need. In 2010 the Association of Chief 
Police Officers (ACPO) commissioned the National Policing Improvement Agency (NPIA), via 
Forensics21, to investigate the feasibility of Accelerated DNA Profiling Technology (ADAPT) and its 
associated benefits. The overall aim and vision of the project was to introduce a technology capable 
of producing a full DNA profile compatible for loading to the NDNAD close to or at the point of 
sampling within an hour [3]. Under this programme the ParaDNA Screening System was categorised 
as a Level 1 DNA Screening Solution meeting the following requirements: 
 
• It should be a basic tool to indicate whether or not human DNA is present within a crime stain 
sample, i.e. it should be a test for DNA. 
• It should provide police forces with the capability for a more robust and reliable decision making 
method. 
• It should make it faster for forces to gain early intelligence. 
• It should be easy to use by non-scientific personnel. 
• The results output should be simple enough to be interpreted by personnel with minimal training. 
 
The ADAPT Initiative reported a potential cost saving of up to £3.25 million per annum if samples 
that did not contain human DNA were successfully screened out [3]. In the interest of continuing the 
important discussion regarding the controlled and careful release of research and development 
ideas into the field of forensics the following article uses the ParaDNA System as a case study in 
taking R&D to market.  
 
2. Materials and methods 
The ParaDNA Screening System consists of the following components:  
Sample collector — A disposable plastic device (Fig. 1a) used in a similar manner as a traditional 
cotton swab. Collection of cellular material occurs through adsorption onto the four plastic tips of 
the device. Material can be recovered from both evidential swabs (indirect sampling — Fig. 1b) or 
directly from an evidence item (direct sampling). After sampling, the collector is inserted into the 4-
well PCR plate (Fig. 1c), introducing the DNA template whilst simultaneously sealing the PCR wells. 
Test kit — Four independent PCR assays pre-loaded into the custom designed 4-well PCR plate (Fig. 
1c). The assays use HyBeacon Technology to amplify and detect 2 STRs and the Amelogenin gender 
marker.  
Analyses software — Controls the instrument (Fig. 1d), analyses the data and displays the screening 
result. The software analyses changes in fluorescence (ΔRFU) as a HyBeacon probe melts away from 
an its amplified allele at a specific melting temperature (TM) between 20 °C and 70 °C. The 
temperature at which this fluorescence change occurs varies with the length of the amplified allele. 
This temperature separation enables the software to attribute a proportion of the overall 
fluorescence change to each possible allele and converts this data into an easily interpretable 
colour-coded ‘DNA Detection’ result as follows:  
 
■ Red— No DNA detected. Fluorescence change consistent with negative control data. 
■ Green — DNA detected. Fluorescence change consistent with positive control data. 
 
In addition to the red/green DNA Detection result, a percentage score provides a relative 
quantitative assessment of the amount of DNA loaded into the reaction, allowing the user to select 
which item to preferentially submit for laboratory analysis if multiple items from the same case are 
obtained. The software also provides gender information if enough template material is amplified. 
In order to assess the ParaDNA Screening System against the NPIA's published specification a 
number of separate structured assessments of the technology were organised under the ADAPT 
programme. Initial trials (beginning March 2011) were followed by a review of documentary 
evidence provided by LGC which measured the acceptance criteria set by the NPIA against 
specification of the Screening System. Concurrent with these trials the technology was undergoing 
continued development and improvement followed by a rigorous forensic validation according to 
published Scientific Working Group on DNA Analyses Methods (SWGDAM) guidelines [4]. 
Independent technical evaluation was then performed by the Centre of Applied Science and 
Technology (CAST) group through the Food and Environment Research Agency (FERA) (July 2012). 
The final part of the ADAPT initiative was assessment of the validated technology in several Police 
Force pilots in the United Kingdom.  
A time line of the development process and external assessments performed is provided in Fig. 2. 
Information regarding the configurations under test at each stage is provided in Table 1. Product 
changes resulting from developmental improvements underwent strict equivalence testing to 
demonstrate a continuity between the original validation data and any newly introduced design 
improvements. 
 
2.1. NPIA initial assessment 
The initial ADAPT trials (February–March 2011) followed a simple side by side format whereby a 
single Scene of Crime Investigator (CSI) from a selected UK Police Force assessed the technology 
alongside a member of the LGC development team. Three trials took place, and each time a different 
Police Force and CSI were invited to take part. Mock samples types were tested comprising: blood 
on glass, blood on denim, cigarette butt, drinks bottle, tools, clothing (sock), lighter, and fingerprint 
on a glass slide. Both indirect and direct methods of collection were assessed. At this point of 
development there was no software to perform analyses and the data was acquired on a Bio-Rad 
CFX96 Real-Time PCR Detection System. 
 
2.2. Validation 
Validation experiments were designed to address the guidelines laid out by the Scientific Working 
Group on DNA Analysis Methods (SWGDAM) [4]. Experiments to characterise each aspect of the 
performance of the ParaDNA Screening System were performed at LGC Forensics, with the inter-
laboratory reproducibility trials performed in collaboration with Florida International University (FIU) 
and the University of Central Florida (UCF). All data were analysed using the ParaDNA software v 
1.0.1.0 except the species specificity experiments which were performed on a Bio-Rad CFX96 Real-
Time PCR Detection System. The success of the Screening System was assessed based on how often 
a positive or negative screening result from the ParaDNA System correlated with a useable SGM+ 
profile when the sample was submitted downstream. Using the successful amplification of 14 or 
more alleles as a benchmark indicator that the SGMPlus profile was ‘usable’, samples were 
categorised as true positives, true negatives, false positives, or false negatives. The data has recently 
been accepted for publication [5]. 
 
2.3. NPIA usability study and CAST testing 
The NPIA with the assistance of three Police Forces undertook usability testing of the ParaDNA 
device in 2012. After training by LGC staff the test user group consisting of both novice and 
experienced Crime Scene Investigators (CSIs) performed a number of tests on the system using 
samples prepared by the NPIA. Whilst mocked-up evidence samples were included in the analyses, 
the purpose of the testing was to assess the usability of the system by non-specialists and not the 
accuracy, sensitivity or reproducibility of data. Testers consisted of staff with varying levels of 
experience and skills. These included non-scientific background administration staff, submissions 
managers and highly experienced CSIs and each completed a questionnaire provided by the NPIA. 
A formal independent assessment of the ParaDNA Screening System was performed by CAST 
through FERA in 2012. This laboratory evaluation analysed experimental samples providing a range 
of amounts of DNA, comprising: buccal swabs, blood on denim, drinking vessel, negative buccal, 
non-human species. The National DNA Database Accreditation Service (NAS) generated the samples. 
All samples were stored in a freezer at −20 °C during transportation and when not in use. All data 
were analysed using final specification chemistry, PCR plastics and Collection Device with success 
measured as whether the ParaDNA Screening System detected DNA on items that were known to 
contain template material. 
 
2.4. Pilots 
LGC, under the supervision of NPIA, undertook field test pilots with several Police Forces for 
ParaDNA technology. These pilots were planned in 4 phases to validate the future operating 
procedure for ParaDNA technology in police hands (Fig. 3). Two Police Forces took part in phases I–
III, whilst a single Police Force was selected to perform phase IV on live case work. The four phases 
of the UK Police pilot programme had predetermined acceptance criteria (Table 2). Mock evidence 
samples for the pilots were provided from both LGC and UK Police Forces. All data was analysed 
using final specification chemistry, PCR plastics and Collection Device. As with the ParaDNA 
Developmental Validation, the successful amplification of 14 or more alleles was used as a 
benchmark indicator that the SGMPlus profile was ‘usable’. Samples were again categorised as true 
positives, true negatives, false positives, or false negatives. 
 
3. Results and discussion 
The results below present a brief overview of the data obtained at each strategic stage in the 
process. The data shows an evolution of the technology from early testing through to deployment 
and provides an account of the ParaDNA Screening Systems route to market.  
 
3.1. NPIA initial assessment 
The more template material there is on an evidence item the more chance it has of entering each of 
the four tubes of the ParaDNA Screening Test. In short, the presence of DNA can be measured 
crudely by a count of the number of tubes seen amplifying. The combined data generated at the 
initial ADAPT trials shows that there is a strong correlation between the number of tubes amplifying 
and the number of SGM+ peaks obtained from the sample after submission to a Forensic Service 
provider (FSP) (Fig. 4). The data also showed little difference in the results generated from the two 
users (LGC and CSI — data not shown). This data shows the ease of technology transfer and also 
confirms that there is a relationship between the amount of DNA template material on an evidence 
item, the amount of amplification product after ParaDNA amplification and the number of peaks 
seen in the subsequent DNA profile. After the initial trial, the NPIA provided a set of end user 
requirements for their level 1 product [3] which were used as the ParaDNA product target 
specifications during the continuing development of the Screening System. Further optimisation of 
the system and software was performed with the main change being the creation of the ParaDNA 
software which sums the area of the amplification peaks observed and provides a DNA Detection 
Score (%).  
 
3.2. Validation 
The validation studies performed at LGC marks the first point where the product was in a robust and 
testable format. The data demonstrates that the ParaDNA Screening System detected human DNA 
from purified DNA samples and swabbed, mocked-up evidence items with similar sensitivity to that 
demonstrated by commonly used STR profiling products. In addition, the ease of use of the ParaDNA 
Screening system by specialist and non-specialist users in several laboratories was demonstrated. 
The production of positive DNA scores from a variety of substrate and swab types and in the 
presence of inhibitors was observed. The validation data has been accepted for publication [5] and 
therefore cannot be duplicated for inclusion in this overview. 
 
3.3. NPIA usability study and CAST testing 
The technology underwent usability testing organised by the NPIA comprising of a questionnaire and 
assessment of the processing speed. The time taken from opening and examining the evidence item 
to obtaining a sample result took 81 min, which was more than the hour initially required on the 
ADAPT initiative specification. In all, nine users from different forces took part providing various 
feedback to the NPIA questionnaire. Upon completion of the usability testing the independent 
assessment by CAST showed the ParaDNA system passed the evaluation with all blood, buccal and 
drinks giving positive results whilst the negative swabs and animal samples did not amplify. 
 
3.4. Pilots 
The UK Police pilot programme began in October 2012. Acceptance criteria for phases I and II were 
all met. Template rich buccal swabs generated high percentage calls together with gender calls. The 
saliva dilution samples showed some variation between users, although the data still demonstrated 
successful technology transfer. The mock evidence items tested in phase III showed that the 
ParaDNA screening system could be successfully incorporated into a routine evidence triage and 
DNA submission process (Table 3), although data from one participating Force gave a higher than 
expected false negative rate. Upon investigation this highlighted a key process step not being 
followed by the end user and the erroneous data was excluded from further analyses with the 
permission of the regulatory bodies. The assessment was repeated with results falling into specified 
pass criteria. For the total data set the false positive and false negative values fell within the 
expected range based on results of the development validation [5]. Phase IV was on live casework 
items (Table 3) selected by the participating Police Force. ParaDNA correctly determined samples as 
having sufficient DNA present to generate a useful profile in 76% of cases (38/50) of which 53% 
(20/38) generated correct gender calls. 14% of all samples would have been correctly screened out. 
The relatively low number of true negatives detected is likely due to the larger number of ‘template 
rich’ items (blood and saliva) screened. Indeed it is clear that the rate of identification of true 
positives and negatives will vary with the sample type highlighted by the fact that no true negatives 
blood samples were identified whilst 26% of the touch samples were successfully screened out. 4% 
of samples were false positives and 6% of samples were false negatives. This proportion of false 
negatives and false positives fell within the products specified performance. The ParaDNA 
technology did not compromise live case work exhibits and the data generated could be used to 
develop a detailed business case which demonstrates the financial benefits of the ParaDNA 
Screening System.  
Recent data from one Police Force who have validated and implemented the ParaDNA Screening 
System for its use as part of their DNA submissions screening procedures have calculated savings in 
the region of £37,000 p.a. in the first year from their operational testing of ParaDNA Screening 
process. Indeed challenging touch evidence items are now pre-screened more frequently alongside 
commonplace cellular samples leading to cost-saving benefits and improved success rates, and the 
screening in of crucial evidence that will have previously not been prioritised for DNA profiling. 
 
4. Summary 
To date, many of the novel technologies or developments in forensic science have come from the 
wider scientific community and been applied to the field rather than from innovation within the field 
itself. The case study presented here represents a product that from its very inception was intended 
to be deployed in the forensics arena. The route to market briefly described above represents the 
combined efforts of a number of different bodies including, research laboratories, industry groups, 
government departments and academic institutions. It has taken more than three years to move 
from a proof of concept to an operationally deployed product with the official launch of the 
ParaDNA Screening System held at the American Academy of Forensic Sciences in March 2013. In 
addition to the work outlined in this manuscript there have been ongoing validation and pilot work 
held in the United States [6].  
It is wholly recognised by all those involved in this endeavour that novel technology developed for 
use in the forensic market needs vigorous testing and careful implementation. It should be 
recognised that forensic science is the application of science to the law and as such the peer 
reviewed publication and acceptance of the underlying principals and interpretation of data should 
ultimately determine if a process is scientifically valid. At the same time it is only through 
cooperation with end users, i.e. the Criminal Justice System, that a sound scientific process can be 
critically assessed and implemented. Therefore for successful development to occur industry 
research scientists, academic bodies and development teams need to fully interact with the wider 
forensic community both to aid in their understanding and acceptance of novel scientific principles 
and for end users to critically assess any new advances in the field of forensic science. 
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 Fig. 1. To use the ParaDNA Screening System simply (a)open the disposable ParaDNA sample 
collector; (b) recover the cellular material from an evidence item; (c) introduce the template 
material into the PCR consumable containing the assay mix; and (d) load on the instrument. 
 
 Fig. 2. The development of the ParaDNA Screening System from proof of principle through product 














Fig. 4. Results from first ADAPT trial showing correlation between number of peaks observed in 
SGM+ profile and number of ParaDNA tubes amplifying for both (a) direct sampling and (b) indirect 
sampling of mock evidence items. The measurement metric evolved from a number of tubes 
amplifying to % DNA Score during the subsequent development process.
  
Table 1 
Configurations under assessment during each stage of the ADAPT initiative. 
 Chemistry Version PCR Consumables Sampling Device PCR Unit Metric used to assess data 
Initial ADAPT trial 1.0.0 and prior Cut PCR plates Prototype v 1 Bio-Rad CFX Number of tubes amplifying 
LGC developmental validation 4.2.0 Cut PCR plates* PARA-050 Bio-Rad CFX  DNA Detection Score (%) 
  LGCSTK005657  PARA-010  
CAST testing 4.2.0 LGCSTK005657 PARA-050 PARA-010 DNA Detection Score (%) 
NPIA usability trial 4.2.0 LGCSTK005657 PARA-050 PARA-010 DNA Detection Score (%) 
UK Police pilots 4.2.0 LGCSTK005657 PARA-050 PARA-010 DNA Detection Score (%) 
*Equivalence shown between cut PCR plates and LGC mouldings during ParaDNA validation 
 
Table 2 
Acceptance criteria proposed for UK Police pilot programme. 
 
Phase Acceptance criteria Samples Number
I - Training
Demonstrate the straightforward training and transfer of technology to Police 
Operators with no major operator issues encountered. Buccal swabs One per user
Obtain posiive feedback on the usability of the system
II - Proficiency
Users to be able to effectively obtain expected DNA results from a range of 
evidence types using the ParaDNA Screening System Saliva dilutions spiked in swabs
3-4 swab replicates 
per user
III - Mock case Samples
The successful incorporation of the ParaDNA Screening System by police Staff into 
their routine evidence triage and DNA submissions process Blood                                        Saliva 92 items
The ParaDNA Screening results correlate to the STR profile success. Touch
The results from the testing demonstrate that the false negative and positives 
were within tge expected range based on the developmental validation for the 
total data
IV - Live case work Show correlation between the screening results and the STR results. 50 items
Demonstrate that the technology does not compromise live casework exhibits
Blood, saliva, touch, DNA swabs, 
training shoes, tape lifts
  
Table 3 
Results of UK Police pilots’ phases III and IV. 
 
 
Pilot study Category Blood n Saliva n Touch n Total data set n
Phase III True positive 100% 14 88.90% 48 33.30% 8 76.10% 70
False positive 0% 0 0% 0 41.60% 10 10.90% 20
True negative 0% 0 0% 0 25% 6 6.50% 6
False negative 0% 0 11.10% 6 0% 0 6.50% 6
Phase IV True positive 100% 5 82% 18 65.20% 15 76% 38
False positive 0% 0 4.50% 1 4.30% 1 4% 2
True negative 0% 0 4.50% 1 26.20% 6 14% 7
False negative 0% 0 9.00% 2 4.30% 1 6% 3
Successful profile defined as returning 14 or more alleles. True positives (ParaDNA Detection Score was green and the STR profile yielded ≥ 14 alleles), true negatives (ParaDNA DNA Detection 
Score was red and the STR profile yielded < 14 alleles), false positives (ParaDNA Detection Score was green and the STR profile yielded <14 alleles), or false negatives (ParaDNA DNA Detection 
Score was red and the STR profile yielded ≥ 14 alleles).
